HUA MEDICINE (SHANGHAI) LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.61 HKD | 0.00% |
|
+1.26% | -18.27% |
| Mar. 28 | Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2023 | 76.61M 10.62M 83.03M | Sales 2024 * | 594M 82.34M 644M | Capitalization | 1.45B 201M 1.57B |
|---|---|---|---|---|---|
| Net income 2023 | -211M -29.24M -229M | Net income 2024 * | -233M -32.29M -253M | EV / Sales 2023 | 22.9 x |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 2.44 x |
| P/E ratio 2023 |
-8.14
x | P/E ratio 2024 * |
-6.25
x | Employees | 177 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 86.36% |
More Fundamentals
* Assessed data
More news
Latest transcript on Hua Medicine (Shanghai) Ltd.
More press releases
| 1 week | +1.26% | ||
| Current month | +1.26% | ||
| 1 month | +13.38% | ||
| 3 months | +0.62% | ||
| 6 months | -1.83% | ||
| Current year | -18.27% |
1 week
1.55
1.66
1 month
1.301.73
Current year
1.292.55
1 year
1.292.96
3 years
1.295.38
5 years
1.299.00
10 years
1.299.00
| Managers | Title | Age | Since |
|---|---|---|---|
Li Chen
FOU | Founder | 61 | 09-11-09 |
Li Changhong
CTO | Chief Tech/Sci/R&D Officer | 55 | - |
Di Hong
COO | Chief Operating Officer | 45 | 21-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Nelsen
CHM | Chairman | 60 | 10-04-22 |
William Keller
BRD | Director/Board Member | 75 | - |
Yiu Wa Tsui
BRD | Director/Board Member | 74 | 18-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.66% | 4 M€ | -27.92% | ||
| 0.00% | 117 M€ | +3.12% | - | |
| 0.00% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 1.61 | 0.00% | 586 000 |
| 24-05-06 | 1.61 | +1.26% | 590,000 |
| 24-05-03 | 1.59 | -1.24% | 294,000 |
| 24-05-02 | 1.61 | +1.26% | 278,000 |
| 24-04-30 | 1.59 | -3.05% | 446,000 |
Delayed Quote Hong Kong S.E., May 07, 2024 at 01:59 am EDT
More quotes
Hua Medicine is a China-based company principally engaged in the drug development business. The Company is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The Company mainly operates its business in the domestic and overseas markets.
Calendar
2024-06-26
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.484
CNY
Average target price
2.892
CNY
Spread / Average Target
+94.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.27% | 202M | |
| +9.15% | 106B | |
| -1.08% | 104B | |
| +6.52% | 23.25B | |
| -11.55% | 22.5B | |
| -7.01% | 18.7B | |
| -37.08% | 17.95B | |
| -9.91% | 16.99B | |
| +7.55% | 14.26B | |
| +40.04% | 12.76B |
- Stock Market
- Equities
- 2552 Stock